Phase III additional clinical study of 111in-pentetreotide (MP-1727): Diagnosis of gastrointestinal hormone producing tumors based on the presence of somatostatin receptors

Tsuneo Saga, Nagara Tamaki, Keiichi Itoi, Tetsuro Yamazaki, Keigo Endo, Goro Watanabe, Hirotaka Maruno, Rikuo Machinami, Kiyoshi Koizumi, Taro Ichikawa, Hiroshi Takami, Miyuki Ishibashi, Atsushi Kubo, Kiyoko Kusakabe, Yukio Hirata, Yuji Murata, Yukitaka Miyachi, Masahiko Tsubuku, Harumi Sakahara, Kazuhiro KatadaNorihisa Tonami, Kazutaka Yamamoto, Junji Konishi, Masayuki Imamura, Ryuichiro Doi, Akira Shimatsu, Shinzaburo Noguchi, Yoshinao Hasegawa, Osamu Ishikawa, Yuji Watanabe, Masayuki Nakajo

研究成果: Article査読

10 被引用数 (Scopus)

抄録

Additional phase III multicenter clinical study was performed to investigate the efficacy, safety, and usefulness of somatostatin receptor scintigraphy using 111In-pentetreotide (MP-1727), which binds to somatostatin receptors. Forty patients were included in the study; Group A: 18 patients, gastrointestinal hormone producing tumors had been detected with conventional imaging modalities, Group B: 22 patients, no tumors had been detected with conventional imaging modalities in spite of high serum hormone levels. By comparing the results of the octreotide suppression test, 12/16 cases (75.0%) of Group A and 11/19 cases (57.9%) of Group B were assessed as "effective." By comparing the results of immunohistological examination. 5/9 cases (55.6%) of Group A and 2/4 cases (50.0%) of Group B were assessed as "effective." Severe adverse events were not observed in any of the evaluable 35 cases. MP-1727 was judged as clinically useful in 11/16 cases (68.8%) of Group A and 5/19 cases (26.3%) of group B. These results suggest that MP-1727 scintigraphy is very useful for the diagnosis and decision of the therapeutic strategy of gastrointestinal hormone producing tumors.

本文言語English
ページ(範囲)185-203
ページ数19
ジャーナルKakuigaku
40
2
出版ステータスPublished - 2003
外部発表はい

ASJC Scopus subject areas

  • 放射線学、核医学およびイメージング

フィンガープリント

「Phase III additional clinical study of 111in-pentetreotide (MP-1727): Diagnosis of gastrointestinal hormone producing tumors based on the presence of somatostatin receptors」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル